Helicobacter最新文献

{"title":"Development and Evaluation of a Multi-Epitope Vaccine Based on P22 Virus-Like Particles Targeting Helicobacter pylori.","authors":"Yalan Zhu, Jiaxue Yang, Chubin Fang, Chuan Wang, Tian Tang","doi":"10.1111/hel.70058","DOIUrl":"10.1111/hel.70058","url":null,"abstract":"<p><strong>Background: </strong>The current first-line treatment for Helicobacter pylori (H. pylori) infection is bismuth-based quadruple therapy. However, the widespread use of antibiotics has contributed to the emergence of antibiotic-resistant strains, thereby increasing the likelihood of treatment failure. This study aimed to develop a multi-epitope H. pylori vaccine, designated P22-C3, based on P22 Virus-like Particles, with the objective of reducing infection rates and preventing transmission.</p><p><strong>Materials and methods: </strong>The structural characteristics of P22-C3 were analyzed using transmission electron microscopy (TEM) and dynamic light scattering (DLS). The safety profile of P22-C3 was evaluated through a series of in vitro and in vivo assays. In vitro assessments included cytotoxicity and proinflammatory factor testing. In vivo evaluations, conducted in immunized mice, involved monitoring changes in body weight, biochemical marker fluctuations, and histopathological examinations. The antibody response and T cell-mediated immunity elicited by P22-C3 were quantified using enzyme-linked immunosorbent assay (ELISA) and flow cytometry, respectively. Immune protection efficacy was assessed through a challenge experiment.</p><p><strong>Results: </strong>P22-C3 successfully self-assembled into T = 7 icosahedral structures with an average diameter of 58 nm. Both in vitro and in vivo experiments confirmed that P22-C3 was safe and well-tolerated. Furthermore, P22-C3 elicited a dose-dependent IgG response and a mixed Th1/Th17 immune profile. In challenge experiments, mice immunized with P22-C3 demonstrated reduced bacterial loads and urease levels in the stomach.</p><p><strong>Conclusion: </strong>P22-C3 was well-tolerated and successfully induced a strong immune response, offering protection against H. pylori infection. These properties make P22-C3 a promising H. pylori vaccine. It is important to note that this study was conducted solely in mice and did not involve human participants; therefore, a clinical trial registration number is not applicable.</p>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 4","pages":"e70058"},"PeriodicalIF":4.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Helicobacter pylori Eradication in Older Individuals: A Systematic Review and Meta-Analysis.","authors":"Sun Jae Moon, Ah Young Lee, Jinseub Hwang, Jun-Young Seo","doi":"10.1111/hel.70059","DOIUrl":"10.1111/hel.70059","url":null,"abstract":"<p><strong>Background: </strong>To determine the clinical effects, efficacy, adverse events, tolerance, and antibiotic resistance of Helicobacter pylori (H. pylori) eradication therapy in the elderly.</p><p><strong>Materials and methods: </strong>We searched Medline, Embase, CINAHL, Cochrane Library, clinical trial registry, conference proceedings portal, and citation screening. We selected randomized controlled trials (RCTs) or cohort designs including participants aged 60 years or older and reported their clinical effects or efficacy as quantitative indices. Meta-analyses were performed using a random effects model.</p><p><strong>Results: </strong>A total of 5172 studies were identified, of which 64 were selected for review. The pooled eradication rate of the 10-day sequential therapy was 91% (95% confidence interval [CI], 86%-93%) and that of the 7-day standard triple therapy was 81% (95% CI, 77%-85%). In addition, 7-day levofloxacin-based TT, 14-day hybrid, 14-day bismuth-based QT, 7-day vonoprazan-based TT, and 14-day TT-PAC regimen in RCTs, and non-bismuth-based QT and susceptibility-based therapy in cohort studies showed eradication rates ≥ 95%. The most prevalent gastrointestinal adverse event varied by regimens, with compliance ranging from 87% to 100%. When populations with a history of eradication were included, antibiotic resistance rates exceeded the national prevalence. Three cohorts (the United States, South Korea, and China) reported a protective effect against gastric cancer, although this varied by index and age subgroup.</p><p><strong>Conclusions: </strong>In the eradication therapy of H. pylori in individuals aged 60 years or older, the 7-day standard triple therapy was unacceptable, and the 10-day sequential therapy was borderline acceptable. The eradication history should be assessed as it may contribute to antibiotic resistance. Although positive reports have emerged regarding the protective effects of gastric cancer on that population, country-specific and conditional recommendations are necessary. Future researchers should report more rigorously on adverse events, tolerance, and antibiotic resistance.</p><p><strong>Protocol registration: </strong>CRD42024617327.</p>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 4","pages":"e70059"},"PeriodicalIF":4.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: Efficacy of Lactobacillus spp. Supplementation in Helicobacter pylori Eradication: A Systematic Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis—Authors' Reply","authors":"Vivek Mishra,&nbsp;Debabrata Dash,&nbsp;Aditya K. Panda,&nbsp;Sushil Kumar Pathak","doi":"10.1111/hel.70054","DOIUrl":"https://doi.org/10.1111/hel.70054","url":null,"abstract":"","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Increasing Trend of the Generational Helicobacter pylori-Naïve Prevalence Among Japanese Individuals Born Between 1925 and 2015: A Systematic Review and Meta-Regression Analysis","authors":"Fumiaki Ishibashi,&nbsp;Chikamasa Ichita,&nbsp;Ayaka Takasu,&nbsp;Ran Li,&nbsp;Yasuhiro Hagiwara,&nbsp;Yutaka Matsuyama,&nbsp;Yuichiro Kemmoto,&nbsp;Chika Kusano,&nbsp;Manami Inoue,&nbsp;Nobutake Yamamichi,&nbsp;Hideki Ishikawa,&nbsp;Takuji Gotoda","doi":"10.1111/hel.70052","DOIUrl":"https://doi.org/10.1111/hel.70052","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The World Health Organization has confirmed that <i>Helicobacter pylori</i> is a carcinogen associated with gastric cancer (GC). Although a recent increasing trend in the prevalence of the <i>H. pylori</i>-naïve status has been reported, the precise values of each generation have not yet been specified. This study aimed to confirm the generational <i>H. pylori</i>-naïve prevalence in Japan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Scientific articles available in PubMed and EMBASE between January 2014 and June 2024 were systematically searched. Publications that specified the generational <i>H. pylori-</i>naïve prevalence were included in the analysis. Publications that did not describe the prevalence of <i>H. pylori</i>-naïve individuals and the definition of <i>H. pylori</i>-eradicated individuals were excluded. A meta-regression analysis with a logistic mixed effect model was conducted to predict the generational prevalence of the <i>H. pylori</i>-naïve status. In this model, birth year was incorporated as a spline function to model non-linear trends, and study differences were included as random effects.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 899 publications were identified. After screening, eight publications were included in the final analysis. Nine different study groups comprising 46,704 individuals included in those publications were identified and analyzed. The calculated <i>H. pylori</i>-naïve prevalence rates among the average cohort were 21.1% for births in 1930, 47.2% for births in 1950, 75.3% for births in 1970, 91.7% for births in 1990, and 97.7% for births in 2010.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The <i>H. pylori</i>-naïve prevalence increased dramatically with more recent birth years and reached a plateau of over 95%, especially after 2000. The current GC screening strategy can be modified based on this finding.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144264604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Three Amoxicillin Doses in Vonoprazan Dual Therapy for Helicobacter pylori Eradication: A Randomized Noninferiority Trial","authors":"Ruolin Peng,&nbsp;Pengpeng Cai,&nbsp;Zhimei Zhang,&nbsp;Shengxiang Lv,&nbsp;Guangxia Chen,&nbsp;Yuling Xu,&nbsp;Bin He,&nbsp;Min Sun,&nbsp;Xiaorong Dai,&nbsp;Kunfeng Yan,&nbsp;Lu Shen,&nbsp;Jianrong Wang,&nbsp;Wei Li,&nbsp;Rui Yin,&nbsp;Jianxin Ge,&nbsp;Duanmin Hu,&nbsp;Kewei Hu,&nbsp;Xiaodan Xu,&nbsp;Hui Li,&nbsp;Chengyu Pan,&nbsp;Zhaotao Duan,&nbsp;Xuefeng Gao,&nbsp;Zhenyu Zhang,&nbsp;Wanli Liu","doi":"10.1111/hel.70050","DOIUrl":"https://doi.org/10.1111/hel.70050","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Limited research has explored the efficacy of reduced amoxicillin dosages in vonoprazan-amoxicillin (VA) dual therapy for <i>Helicobacter pylori</i> eradication in China, and this study aimed to assess the noninferiority of these lower dosages compared to the standard high dose (3 g/d).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a noninferiority study with a −10% margin. <i>H. pylori</i>-positive patients from 13 centers in Jiangsu Province, China, were randomly assigned in a 1:1:1 ratio to receive a 14-day treatment, consisting of vonoprazan (20 mg BID) and high-dose amoxicillin (1 g TID, HVA), medium-dose amoxicillin (1 g BID, MVA), or low-dose amoxicillin (0.5 g TID, LVA). The eradication rates, adverse events (AEs), and medication adherence were compared.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>From January 13, 2023 to July 6, 2024, a total of 900 patients were enrolled. According to the intention-to-treat (ITT) and per-protocol (PP) analyses, the eradication rates for HVA, MVA, and LVA groups were 93.2% and 93.2%, 91.6% and 91.5%, and 87.0% and 86.8%, respectively. The efficacy of MVA was noninferior to HVA in ITT analysis (difference: −1.6%, 97.5% CI: −7.0% to 3.8%, <i>p</i> &lt; 0.001) and PP analysis (difference: −1.7%, 97.5% CI: −7.1% to 3.7%, <i>p</i> &lt; 0.001); LVA's effectiveness was less than HVA in ITT analysis (difference: −6.2%, 97.5% CI: −12.2% to −0.2%, <i>p</i> = 0.076) and PP analysis (difference:-6.4%, 97.5% CI: −12.4% to −0.3%, <i>p</i> = 0.089). The incidence of AEs and medication compliance among the three groups was similar.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>A 14-day VA regimen requires ≥ 2 g/d amoxicillin to maintain noninferior eradication efficacy versus 3 g/d, supporting dose reduction without compromising effectiveness.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>ClinicalTrials.gov identifier: NCT05649540</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144232465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authors' Reply to the Letter on “Is Tailored Bismuth Quadruple Therapy (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First-Line Helicobacter pylori Eradication Treatment More Effective? A Three-Arm, Multicenter Randomized Clinical Trial”","authors":"Zhengchen Yu,&nbsp;Wenjuan Shen,&nbsp;Guochun Lou,&nbsp;Yan Li,&nbsp;Ziming Xie,&nbsp;Jun Ye","doi":"10.1111/hel.70049","DOIUrl":"https://doi.org/10.1111/hel.70049","url":null,"abstract":"<div>\u0000 \u0000 <p>We appreciate the valuable comments and thoughtful critique offered by the reader regarding our study on tailored bismuth quadruple therapy based on fecal molecular susceptibility testing in first-line <i>Helicobacter pylori</i> eradication. In our response, we have sought to clarify the methodological rationale underlying our statistical analysis and terminology usage, particularly regarding superiority and non-inferiority testing. We have also addressed concerns regarding assessing prior macrolide exposure, outlining the practical considerations that informed our study design. We trust that our clarifications will help to elucidate the study's context and findings further, and we welcome continued academic dialogue on this important topic.</p>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144220402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Roles of Gastric Non-Helicobacter pylori Helicobacter Species in Gastric Disease Development: A Review","authors":"Mitsushige Sugimoto,&nbsp;Emiko Rimbara,&nbsp;Masaki Murata,&nbsp;Yoshio Yamaoka","doi":"10.1111/hel.70051","DOIUrl":"https://doi.org/10.1111/hel.70051","url":null,"abstract":"<div>\u0000 \u0000 <p>Gastric <i>Helicobacter</i> species, including <i>Helicobacter pylori</i> and non-<i>Helicobacter pylori Helicobacter</i> (NHPH) species, are gram-negative fastidious bacteria that colonize the stomachs of both humans and animals such as pigs, dogs, cats, and monkeys. The <i>H. pylori</i> infection rate is decreasing due to improved living conditions and increased opportunities for <i>H. pylori</i> eradication therapy in developed countries. However, concerns about NHPH infection-induced gastric diseases are growing, especially low-grade gastric mucosa-associated lymphoid tissue lymphoma. Although NHPH infections have been reported for 30 years, especially <i>H. suis</i> infections, evidence of the correct infection rate, route of infection to humans, and direct and indirect associations with gastric diseases are insufficient. Presently, NHPH infection can be diagnosed using histopathological and immunohistochemical findings, polymerase chain reaction, culture tests, or enzyme-linked immunosorbent assays. Several basic and clinical studies have begun to report the bacteriologic characteristics and routes of NHPH infection. In addition, the high effectiveness of eradication therapy using a combination of an acid inhibitor and two types of antibiotics, which is the same eradication regimen for <i>H. pylori</i> infection, has been reported. However, evidence on antibiotic resistance, appropriate dosing dosage, or drug type provided by randomized control trials is lacking. Several issues regarding the etiology, virulence, diagnosis, and treatment of NHPH infections should be addressed in the future.</p>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144206735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: “Parietal Cell Antibody Levels Among Chronic Gastritis Patients in a Country With Low Helicobacter pylori Infection: Epidemiology, Histopathological Features, and H. pylori Infection”","authors":"Xiaopei Guo,&nbsp;Manon C W Spaander,&nbsp;Gwenny M Fuhler","doi":"10.1111/hel.70053","DOIUrl":"https://doi.org/10.1111/hel.70053","url":null,"abstract":"&lt;p&gt;We read with great interest the article titled “Parietal Cell Antibody Levels Among Chronic Gastritis Patients in a Country with Low &lt;i&gt;Helicobacter pylori&lt;/i&gt; Infection: Epidemiology, Histopathological Features, and &lt;i&gt;H. pylori&lt;/i&gt; infection” by Amalia et al. [&lt;span&gt;1&lt;/span&gt;]. In this study, the authors investigated the prevalence of autoimmune gastritis (AIG), and its association with &lt;i&gt;Helicobacter pylori&lt;/i&gt; (&lt;i&gt;H. pylori&lt;/i&gt;) infection status and gastric histopathological features in the Indonesian population. Given the previously reported high incidence of gastritis and relatively low &lt;i&gt;H. pylori&lt;/i&gt; infection rates in this region, exploring other causes of gastritis, such as AIG, is essential for improving diagnostic accuracy and guiding clinical risk management [&lt;span&gt;2&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;While the authors conducted a comprehensive analysis of parietal cell antibody (PCA) levels and its association with clinicopathological features, several aspects of the study's methodology and interpretation raise concerns and warrant further clarification. A key observation of this study is the reported 78.99% prevalence of PCA positivity among 113 Indonesian patients with chronic gastritis and 25 healthy controls, while only one patient was diagnosed with AIG. The authors suggest that this discrepancy might be due to &lt;i&gt;H. pylori&lt;/i&gt;-associated immune activation. However, we think it may also reflect the combined impact of overly strict diagnostic criteria for AIG and the inappropriate interpretation of PCA results.&lt;/p&gt;&lt;p&gt;In the diagnostic methods, AIG was defined based on the PCA positivity, absence of &lt;i&gt;H. pylori&lt;/i&gt; infection, histopathological features associated with AIG, and sparing of the antrum. We understand the concern that coexisting &lt;i&gt;H. pylori&lt;/i&gt; infection may complicate the diagnosis of AIG, as it can cause histopathological changes that resemble AIG. But we note that neither antrum sparing nor negative &lt;i&gt;H. pylori&lt;/i&gt;-negative status should be a required criterion for AIG diagnosis. Our previous findings have shown that AIG can coexist with &lt;i&gt;H. pylori&lt;/i&gt; infection, and hence patients may present with antral inflammation or atrophy. Such patients still show characteristic serological features similar to AIG patients without &lt;i&gt;H. pylori&lt;/i&gt; infection, including decreased pepsinogen (PG) I levels and elevated gastrin 17 [&lt;span&gt;3&lt;/span&gt;]. Additionally, they may exhibit pathological findings such as enterochromaffin-like (ECL) cell hyperplasia [&lt;span&gt;4&lt;/span&gt;], which was not investigated in the study by Amalia et al. Therefore, we think the criteria used may have led to underdiagnosis of AIG in the Indonesia cohort. Rather than excluding patients with &lt;i&gt;H. pylori&lt;/i&gt; infection or antrum inflammation/atrophy, more specific diagnostic tests should be considered to improve the diagnosis of AIG, especially given this is the first study reporting AIG prevalence in this region.&lt;/p&gt;&lt;p&gt;Adding to these diagnostic challenges Beyond these di","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hel.70053","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144206830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Systemic Impact of Helicobacter pylori Infection on the Microbiome of Whole Digestive Tract Based on Mucosal, Gastric Juice, and Fecal Specimens","authors":"Yuxin Wang,&nbsp;Kai Zhou,&nbsp;Yuexi Zhang,&nbsp;Cailing Li,&nbsp;Yuxin Zhang,&nbsp;Xinlu Ren,&nbsp;Changmin Mi,&nbsp;Lingling Ma,&nbsp;Yuqi Duan,&nbsp;Mengqi Liu,&nbsp;Guangjie Ping,&nbsp;Xueli Tian,&nbsp;Zhiqiang Song","doi":"10.1111/hel.70047","DOIUrl":"https://doi.org/10.1111/hel.70047","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Recent studies have found that in addition to directly impacting the gastric microbiome, &lt;i&gt;Helicobacter pylori&lt;/i&gt; (&lt;i&gt;H. pylori&lt;/i&gt;) infection may cause intestinal microbial dysbiosis. However, most existing studies on the influence of &lt;i&gt;H. pylori&lt;/i&gt; infection on the intestinal microbiome used fecal specimens with inconsistent conclusions. Only one limited study on 8 &lt;i&gt;H. pylori&lt;/i&gt;-infected patients has previously assessed the impact of &lt;i&gt;H. pylori&lt;/i&gt; infection on the microbiome of the entire gastrointestinal tract, finding no significant effect on the bacterial composition of the lower gastrointestinal tract.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This single-center cross-sectional study collected mucosa of the esophagus, stomach, small intestine, and colon, as well as gastric juice and feces from 120 participants of the &lt;i&gt;H. pylori-&lt;/i&gt;infected group (HIG) and 30 of the healthy control group (HCG). 16S rRNA sequencing was applied to analyze the bacterial composition and functional pathways, and metagenomics was adopted to assess the composition of viruses, eukaryotes, and archaea in the feces, as well as the antibiotic resistance gene (ARG) and virulence factors of bacteria (VF).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Compared with the HCG, the alpha and beta diversity of bacteria in the mucosa of the whole digestive tract and the gastric juice of the HIG showed significant changes, with increased microbial dysbiosis index and significantly different compositions at the phylum and genus levels. Functional pathway analysis revealed that the metabolic characteristics of the flora changed in the HIG, with site-specific differences. Fecal specimens demonstrated no significant differences in the above indicators between the two groups. In addition, feces-based metagenomic analysis revealed that only eukaryotes had higher diversity in the HIG, whereas viruses and archaea showed no significant changes; the Shannon index of ARG increased; and VF showed no significant change.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This study revealed that &lt;i&gt;H. pylori&lt;/i&gt; infection significantly influenced the diversity, composition, and metabolic functional pathway of bacteria in different parts of the digestive tract and the gastric juice. Moreover, fecal microbial composition may not fully represent the mucosal microbial composition of the gastrointestinal tract.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Trial Registration&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Chinese Clinical Trial Registry: ChiCTR2300073419&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 ","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144148629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dr Martin Bingham Skirrow—A Passionate Microbiologist and Early Advocate for Helicobacter pylori","authors":"Cliodna McNulty","doi":"10.1111/hel.70048","DOIUrl":"https://doi.org/10.1111/hel.70048","url":null,"abstract":"","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144148628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}